drugset / Trial / NCT00542217

Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection

NCT00542217

Phase 1 Completed 24 enrolled HiberCell, Inc.
RandomizedParallel-groupTriple-blind

Summary

The purpose of this trial is to the assess the safety, pharmacodynamics, and pharmacokinetics of escalating doses of Imprime PGG™ Injection in healthy volunteers.

Timeline

Start
2005-12
Primary completion
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imprime PGG Other / unclassified 0.5 mg/kg Intravenous
Comparator Imprime PGG Other / unclassified 1 mg/kg Intravenous
Comparator Imprime PGG Other / unclassified 2 mg/kg Intravenous
Comparator Imprime PGG Other / unclassified 4 mg/kg Intravenous
Comparator Imprime PGG Other / unclassified 6 mg/kg Intravenous

Indications

No indication recorded.